×
0.097560975609756 -0.0548780487804878 -0.0121951219512195 -0.0426829268292683 -0.0487804878048781 -0.0731707317073171 -0.0731707317073171 -0.0975000000000001
Stock impact report

Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia

Cyclacel Pharmaceuticals, Inc (CYCC)  More Company Research Source: GlobeNewswire
Last cyclacel pharmaceuticals, inc earnings: 8/13 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.cyclacel.com/investor-relations
PDF BERKELEY HEIGHTS, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral therapies that target various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced the presentation by investigators led by William Plunkett, PhD, Professor and Deputy Chair, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, of preclinical data demonstrating strong synergy between Cyclacel’s CDK2/9 inhibitor, CYC065, and  the Bcl-2 inhibitor, venetoclax (ABT-199, AbbVie) in chronic lymphocytic leukemia (CLL) samples obtained from patients. The data were presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 14-18, 2018 in Chicago, Illinois. “The MD Anderson data show that the combination of CYC065 and venetoclax is strongly synergistic in primar [Read more]
Impact snapshot Event time: CYCC
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last price
VWAP
High:
Max up
High:
Low:
Max down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Opt-in for
CYCC alerts
from News Quantified
Opt-in for
CYCC alerts

from News Quantified
Opt-in for
CYCC alerts

from News Quantified